Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.
Type:
Application
Filed:
September 4, 2012
Publication date:
January 3, 2013
Applicants:
Robert Koch Institute, Novartis Vaccines and Diagnostics SRL
Inventors:
Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
Type:
Application
Filed:
March 26, 2010
Publication date:
February 23, 2012
Applicant:
Bundersrepubik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes
Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
Type:
Grant
Filed:
October 23, 2007
Date of Patent:
May 25, 2010
Assignee:
Bundersrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes
Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
Type:
Grant
Filed:
September 23, 1998
Date of Patent:
August 21, 2007
Assignee:
Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes
Abstract: The present invention provides methods of suppressing demyelinating inflammatory disorders in a patient by administering to the patient a compound that inhibits binding of B7RP-1 to ICOS or inhibits signaling through the B7RP-1 pathway. Various therapeutic regimens are provided. Methods of identifying such compounds are also provided. The present invention further provides kits and pharmaceutical compositions useful in the present methods.
Type:
Application
Filed:
June 26, 2002
Publication date:
January 1, 2004
Applicants:
Millennium Pharmaceuticals, Inc., Robert Koch-Institutes